Octave Specialty (OSG) Current Deferred Revenue (2010 - 2026)

Octave Specialty's Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $198.7 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 9.53% year-over-year to $198.7 million in Q1 2026; TTM through Mar 2026 was $198.7 million, a 9.53% increase from a year earlier, with the FY2025 full-year figure at $187.2 million, up 2.59% from the prior year.
• Current Deferred Revenue climbed to $198.7 million in Q1 2026 per OSG's latest filing, from $187.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $458.0 million in Q3 2024 and bottomed at $85.4 million in Q4 2022.
• The 5-year median for Current Deferred Revenue is $359.0 million (2022), against an average of $296.3 million.
• Across the five-year window, Current Deferred Revenue surged 754.15% in 2022 and plunged 57.72% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $85.4 million in 2022, then soared by 81.32% to $154.9 million in 2023, then advanced by 17.8% to $182.4 million in 2024, then climbed by 2.59% to $187.2 million in 2025, then grew by 6.15% to $198.7 million in 2026.
• Per Business Quant, the three latest OSG Current Deferred Revenue figures stand at $198.7 million (Q1 2026), $187.2 million (Q4 2025), and $197.1 million (Q3 2025).